🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in France / NCT04493749
Active, not recruiting Observational

Clinical Performance of Withings Move ECG Software for Atrial Fibrillation Detection

NCT04493749 · tracked via the Priya Life Science France tracker
Sponsor
Phase
Observational
Started
2019-12-20
Last updated
2026-02-18

Condition(s) studied

Atrial Fibrillation

Investigational drug(s) / intervention(s)

ECG measurement

ECG measurement: Simultaneous recording of a single-lead ECG signal with the Withings Move ECG and ECG signal for the reference 12-lead ECG

Study summary

Withings Move ECG watch is designed to record ECG and detect automatically atrial fibrillation. The aim of this study is to validate the performance of Move ECG watch to detect atrial fibrillation compared to a reference 12-lead ECG.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * male or female who are 18 years or older * Subject who signed the written informed consent form Exclusion Criteria: * Vulnerable subject with regard to regulations * Pregnant, parturient or breastfeeding woman, * Subject who is deprived of liberty by judicial, medical or administrative decision, * Underage subject, * Legally protected subject, or subject who is unable to sign the written informed consent form, * Subject who is not beneficiary or not affiliated to a social security scheme, * Subject within several of the above categories, * Subject who refused to participate in the study, * Subject in physical incapacity to wear a wrist-worn watch * Subject with electrical stimulation by pacemaker

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Institut Cœur Paris Centre Turin Paris Île-de-France Region
Hopital Europeen Georges Pompidou Paris Île-de-France Region
Centre Cardiologique du Nord Saint-Denis Île-de-France Region

More Withings trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04493749 on ClinicalTrials.gov ↗ ← All trials in France